WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2024)
Top general drug manufacturer stocks in 2024 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

Industry: Drug Manufacturers - Gene...
Ticker
Company
Dividends Score
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
BMY
BRISTOL MYERS SQUIBB CO
$102.63B4.55%59.50%$0.6000$2.3174%0
JNJ
JOHNSON & JOHNSON
$388.73B2.95%42.40%$1.1900$4.7654%02024-03-05
AZN
ASTRAZENECA PLC
$198.92B2.26%75.50%$0.9850$1.4544%92024-03-25
GILD
GILEAD SCIENCES INC
$89.82B4.16%66.10%$0.7500$3.0069%02024-03-142024-03-28
SNY
SANOFI
$121.04B3.98%82.10%$1.9031$1.9067%2
GSK
GSK PLC
$84.97B3.47%45.10%$0.4061$1.4560%102024-04-11
BIIB
BIOGEN INC
$31.54BN/A0.00%N/AN/AN/AN/A
NVS
NOVARTIS AG
$206.39B3.44%48.50%$3.4694$3.4760%22024-03-07
LLY
ELI LILLY & CO
$716.12B0.62%80.60%$1.3000$4.6910%02024-03-08
PFE
PFIZER INC
$149.98B6.21%434.20%$0.4200$1.6585%02024-03-01
AMGN
AMGEN INC
$146.75B3.16%50.90%$2.2500$8.6456%02024-03-07
ABBV
ABBVIE INC
$310.99B3.40%219.40%$1.5500$5.9959%02024-04-122024-05-15
GRFS
GRIFOLS SA
$5.16BN/A0.00%$0.4562N/AN/A4
MRK
MERCK & CO INC
$322.03B2.33%2,114.30%$0.7700$2.9645%02024-03-142024-04-05
AMRN
AMARIN CORP PLC
$439.42MN/A0.00%N/AN/AN/AN/A
OGN
ORGANON & CO
$4.45B1.61%14.00%$0.2800$0.2832%0
SCLX
SCILEX HOLDING CO
$353.99MN/A0.00%N/AN/AN/AN/A

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Mar 2024?

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) is the top general drug manufacturer stock with a Zen Score of 64, which is 21 points higher than the general drug manufacturer industry average of 43. It passed 24 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock lose -26.41% over the past year, underperforming other general drug manufacturer stocks by -53 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $60.40, an upside of 19.01% from Bristol Myers Squibb Co's current stock price of $50.75.

Bristol Myers Squibb Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 15 analysts covering Bristol Myers Squibb Co, 20% have issued a Strong Buy rating, 0% have issued a Buy, 73.33% have issued a hold, while 0% have issued a Sell rating, and 6.67% have issued a Strong Sell.

2. Johnson & Johnson (NYSE:JNJ)


Johnson & Johnson (NYSE:JNJ) is the second best general drug manufacturer stock with a Zen Score of 60, which is 17 points higher than the general drug manufacturer industry average of 43. It passed 22 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock return 5.3% over the past year, underperforming other general drug manufacturer stocks by -21 percentage points.

Johnson & Johnson has an average 1 year price target of $177.50, an upside of 9.99% from Johnson & Johnson's current stock price of $161.38.

Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Johnson & Johnson, 25% have issued a Strong Buy rating, 25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Astrazeneca (NASDAQ:AZN)


Astrazeneca (NASDAQ:AZN) is the third best general drug manufacturer stock with a Zen Score of 57, which is 14 points higher than the general drug manufacturer industry average of 43. It passed 21 out of 38 due diligence checks and has strong fundamentals. Astrazeneca has seen its stock lose -1.56% over the past year, underperforming other general drug manufacturer stocks by -28 percentage points.

Astrazeneca has an average 1 year price target of $81.67, an upside of 27.29% from Astrazeneca's current stock price of $64.16.

Astrazeneca stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Astrazeneca, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 12 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) has an annual dividend yield of 6.21%, which is 3 percentage points higher than the general drug manufacturer industry average of 3.24%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 434.2% indicates that its high dividend yield might not be sustainable for the long-term.

2. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 4.55%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.24%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 59.5% indicates that its dividend yield is sustainable for the long-term.

3. Gilead Sciences (NASDAQ:GILD)


Gilead Sciences (NASDAQ:GILD) has an annual dividend yield of 4.16%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.24%. Gilead Sciences's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Gilead Sciences's dividend has shown consistent growth over the last 10 years.

Gilead Sciences's dividend payout ratio of 66.1% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -1.04% in the last day, and down -1.87% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are down.

What are the most undervalued general drug manufacturer stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

1. Grifols Sa (NASDAQ:GRFS)


Grifols Sa (NASDAQ:GRFS) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Grifols Sa has a valuation score of 100, which is 49 points higher than the general drug manufacturer industry average of 51. It passed 7 out of 7 valuation due diligence checks.

Grifols Sa's stock has dropped -13.28% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -40 percentage points.

2. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Sanofi has a valuation score of 86, which is 35 points higher than the general drug manufacturer industry average of 51. It passed 6 out of 7 valuation due diligence checks.

Sanofi's stock has gained 2.13% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -25 percentage points.

3. Astrazeneca (NASDAQ:AZN)


Astrazeneca (NASDAQ:AZN) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Astrazeneca has a valuation score of 86, which is 35 points higher than the general drug manufacturer industry average of 51. It passed 6 out of 7 valuation due diligence checks.

Astrazeneca's stock has dropped -1.56% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -28 percentage points.

Are general drug manufacturer stocks a good buy now?

35.29% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 10.86% over the next year.

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 152.91x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.